and the anti-apoptotic molecule Bcl-2 was lower in comparison to the Apo2L/TRAIL-resistant tumor. Conclusion: These results indicate that both Apo2L/TRAIL-sensitive and -resistant colon tumors will respond to a combination of CPT-11 and Apo2L/TRAIL and predict that this will be useful in the treatment of human colon cancers in a clinical setting.
Introduction
Successful development of anti-cancer therapies relies on demonstrating and optimizing the anti-tumor efficacy of therapeutics in a spectrum of preclinical models, each of which has strengths and weaknesses. Often, the response of human cell lines and xenografts has not correlated with the clinical efficacy observed in clinical trials. In one NIH study, for example, it was found that only cell line xenografts of non-small lung cancer correlated with clinical activity in tumors of the same histology [1] . A recent retrospective analysis found that although the cell line xenograft model was predictive for non-small cell lung and ovarian cancers, panels of colon or breast tumor cell line xenografts failed to predict clinical performance in phase II studies for these tumors [2] . For this reason, investigators continue to explore the relevance of new models. We and others [3, 4] have developed and ap-plied a patient tumor/SCID mouse xenograft model to evaluate the effect(s) of novel therapies and treatment regimens on actual patient tumors [5] [6] [7] in order to extend observations made with human cell lines. These human tumor xenografts recapitulate both the range of histology and diversity of the original tumors and have the advantage of using low-passage human tumors which have never been cultured in vitro. Thus they are a valuable preclinical bridge to the clinic.
Apo2L/TRAIL (tumor-necrosis factor apoptosis-inducing ligand) is a member of the TNF family [8] [9] [10] . Similar to TNF and FasL, Apo2L/TRAIL is a type II transmembrane protein that can induce apoptosis in malignant cells [11, 12] and does not exhibit the normal tissue or systemic toxicity of TNF or anti-Fas antibodies or FasL [13, 14] . Apo2L/TRAIL induces apoptosis through its interaction with two death domain-containing receptors, DR4 [15, 16] and DR5 [16, 17] . Following Apo2L/ TRAIL engagement in these receptors, caspase-8 is activated and triggers cell death, either by directly activating downstream effector caspases, e.g. caspase-3, and/or by recruiting the mitochondrial pathway to cell death [9, 10] . Not all cancer cells undergo apoptosis when treated with Apo2L/TRAIL and it has been shown that combination of Apo2L/TRAIL with a variety of chemotherapeutic agents can sensitize resistant cells and result in an improved anti-tumor effect [9] .
Previous work on the effects of Apo2L/TRAIL has been largely carried out on long-established cell lines either in vitro or in vivo. We have previously shown, using the SCID mouse/human tumor xenograft model to evaluate the effects of Apo2L/TRAIL on human colon cancer, that three different human tumors show varying degrees of sensitivity to Apo2L/TRAIL [7] . In this study, we have identified a human colon tumor that is inherently resistant to Apo2L/TRAIL and compared it to a tumor that is sensitive to the same dose of Apo2L/TRAIL. We found a correlation between total expression levels of BAX and Bcl-2, and sensitivity of these two tumors to apoptosis induced by ApoL/TRAIL alone. Furthermore, we found that combination therapy with CPT-11 enhanced the anti-tumor effect of Apo2L/TRAIL, resulting in increased tumor growth inhibition than was achieved with either agent alone in both the Apo2L/TRAIL-sensitive and -resistant tumors. These results predict that both Apo2L/ TRAIL-sensitive and -resistant tumors will respond to treatment with Apo2L/TRAIL in combination with CPT-11 and thus this validates what has been observed for some cell lines and supports the development of this therapeutic strategy.
Material and Methods

Colon Tumor Model
The SCID mouse-human tumor xenograft model used in these experiments has been described previously [7] . Pieces of human colon tumors obtained from surgical specimens (provided by the Tissue Procurement Facility at the Roswell Park Cancer Institute) were cut into 2 ! 2 mm pieces in tissue culture medium and implanted subcutaneously into 2-3 SCID mice. Tumors that grew to 1 cm in diameter were resected and serially passaged. Tumors that grew in the second passage were considered to have successfully engrafted. Tumors that successfully engrafted were subsequently serially passaged into several mice thereby providing sufficient tumor material for experiments with large numbers of mice.
SCID Mice
CB-17 SCID/SCID mice were used at 6-8 weeks of age and kept under sterile conditions in pathogen-free environment. Mice were provided with sterile water and food ad libitum, and all manipulations were carried out aseptically inside a laminar flow hood.
Materials
Apo2L/TRAIL was generously provided by Genentech (San Francisco, Calif., USA). Irinotecan hydrochloride (CPT-11) was obtained from Upjohn (Kalamazoo, Mich., USA). Antibodies used were rabbit polyclonal antibodies for DR4 (PC397) and DR5 (PC392) from Oncogene Research Products (Cambridge, Mass., USA). Rabbit polyclonal antibodies for DcR1 (No. 550622) and DcR2 (No. 559684) were obtained from BD PharMingen (San Diego, Calif., USA). Mouse monoclonal antibodies for BAX (No. 610982) were obtained from BD Transduction Laboratories (San Diego, Calif., USA) and reported to be reactive to dogs and humans. Mouse monoclonal antibodies to Bcl-2 (No. 556354) and rabbit polyclonal antibody for cFLIP (No. 556567) were obtained from BD PharMingen. All antibodies were reported to be against human proteins.
Experimental Design
Engrafted tumors were used as donor tumors to implant experimental groups of mice all bearing the same patient's tumor. Mice were randomly divided into control or treatment groups of 6 mice each. Treatment was initiated when the tumors reached approximately 4-5 mm in diameter (a mean volume of 50 mm 3 ). To assess sensitivity to Apo2L/TRAIL alone, Apo2L/TRAIL (500 g/200 l) was administered daily for 14 days by intraperitoneal injection. To investigate the effects of Apo2L/TRAIL and CPT-11 in combination, Apo2L/TRAIL (500 g/200 l) was given daily by intraperitoneal injection for 14 days, and CPT-11 (10 or 20 mg/ kg) was administered three times per week by intravenous injection. Animals (5 or 6 mice/group) received two of these treatment cycles separated by a 2-week interval [7] . Tumors were measured three times a week and the relative tumor volumes were calculated. Mice were sacrificed by cervical dislocation and the tumors were removed, fixed in neutral buffered formalin, and either embedded in paraffin and/or snap-frozen for further study.
Western Blot Analysis
One mouse was removed from each group on day 3 of treatment. Each tumor was resected and pieces of the tumor xenografts were homogenized in lysis buffer (containing 20 m M Tris, pH 7.5, 120 m M NaCl, 100 m M NaF, 0.5% nonionic P 40 , 200 M Na 3 VO 4 , 50 m M ␤ -glycerophosphate, 10 m M NaPPi, 4 m M PMSF, 10 g/ml leupeptin, 2 m M benzamidine and 10 g/ml aprotinin). Protein concentration of the lysates was assessed using a colorometric assay (BioRad, Hercules, Calif., USA). Equal amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore, Bedford, Mass., USA). After blocking with 5% nonfat milk in PBST (PBS with 0.1% Tween) for 1 h at room temperature, membranes were incubated overnight at 4 ° C with specific antibodies. Membranes were then washed with PBST and incubated further at room temperature for 1 h with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies. The integrated pixel densities of immunoreactive electrophoretic bands were calculated using Image Quant software from Molecular Dynamics (Sunnyvale, Calif., USA), normalized to the corresponding density of the actin bands, and calculated as a factor of the control.
Immunohistochemistry TUNEL Assay. To detect apoptotic cells in tumor sections, the ApopTag Plus peroxidase in situ apoptosis detection kit (Intergen, Purchase, N.Y., USA) was used. Five-micrometer-thick paraffinembedded tumor sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. Tissue sections were incubated in 20 g/ml proteinase K (Dako, Carpinteria, Calif., USA) at room temperature for 15 min. Following rinsing in distilled water, endogenous peroxidase was blocked by incubating slides in 3% hydrogen peroxide in 0.05 M phosphate buffer containing 0.145 M sodium chloride (PBS), pH 7.4, for 5 min. After washing with PBS, the sections were incubated with equilibration buffer and then TdT enzyme in a humidified chamber at 37 ° C for 60 min. Slides were subsequently put into prewarmed working strength stop buffer for 10 min. After rinsing in PBS, the sections were incubated with anti-digoxigenin-peroxidase conjugate for 30 min. Bound antibody was localized with diaminobenzamidine (Peroxidase Substrate Kit; Vector Laboratories, Burlingame, Calif., USA) and slides were counterstained with hematoxylin. To quantify apoptosis, at least 2,000 cells were counted under the microscope in several random fields of each section. The number of TUNEL staining-positive cells was divided by the total number of cells counted, and the result was expressed as percentage of apoptotic cells. Evaluation of the p53 status was accomplished using monoclonal antibody clone DO7 (Novocastra) and antigen retrieval with steam and antigen retrieval buffer (Dako).
Sequencing of Human p53 Genes
Total RNA from 11501 and 11124 tumors was isolated using TRIzol (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's recommendations. Two micrograms of RNA were reverse transcribed to generate the first cDNA strand using the Superscript II system (Invitrogen).
To distinguish murine from human p53, primers were designed 5 -and 3 -in non-conserved regions of the DNA binding domain (DBD) of the p53 gene. The primer sets used for the amplification are forward primer, 5 -GCCGTCCCAAGCAATG-GATGA-3 and reverse primer, 5 -AGCTCGTGGTGAGGCT-CCCCTTTCTT-3 . To test the specificity of the primers, p53 was amplified in gradient PCR reactions (increasing annealing temperature) using p53+/+ cDNA from both murine and human cell lines. The determined optimal conditions were used in a PCR reaction using the Accuprime enzyme (Invitrogen) and the 11124 and 11501 cDNA. Several amplicons from different PCR reactions were then gel purified and cloned into pDrive (Qiagen, Valencia, Calif., USA) before sequencing by the Roswell Park Cancer Institute Biopolymer Facility.
Statistical Analysis
Statistical significance was determined by comparing the final relative volumes of tumors. Student's t test was used for experiments evaluating the efficacy of Apo2L/TRAIL alone. One-way ANOVA followed by Tukey's test was used for experiments evaluating the efficacy of Apo2L/TRAIL in combination with CPT-11. Differences were considered significant if p ! 0.05.
Results
Characterization of the Responses of Colon Tumors to Apo2L/TRAIL Alone
We have previously reported the responses of three different human colon tumors to Apo2L/TRAIL alone using a human tumor-SCID model, and varying degrees of sensitivity were noted [7] . Characterization of a fourth colon tumor led to the identification of a tumor that is comparatively resistant to Apo2L/TRAIL. As seen in figure 1 a, tumor 11124 is highly sensitive to Apo2L/TRAIL and the growth rate was significantly reduced in the Apo2L/TRAIL-treated group compared with that of the control group (p ! 0.001). Although tumor growth resumed following cessation of treatment, the difference in tumor size was still significant on day 29 (p ! 0.001). In contrast, tumor 11501 was resistant to Apo2L/TRAIL and, while treated tumors were slightly smaller than those of the control group, this difference was not statistically significant at either time point ( fig. 1 b) . These results demonstrate that human colon cancers which are directly derived from patients display both sensitivity and resistance to Apo2L/TRAIL.
The CPT-11 and Apo2L/TRAIL Combination Enhanced Anti-Tumor Efficacy
Because the dose and schedule of Apo2L/TRAIL evaluated here did not suppress tumor growth completely, the response of these tumors to combination treatment with Apo2L/TRAIL and the chemotherapeutic drug CPT-11 was evaluated. To extend our earlier study on tumorbearing mice which were treated for only 14 days, we wanted to evaluate whether tumor growth could be more effectively controlled with a longer duration of treatment. Therefore, mice were treated with 500 g Apo2L/TRAIL alone and in combination with either 10 or 20 mg/kg CPT-11 for 14 days, and after a 2-week rest, treatment was resumed for 2 weeks. Evaluation of the tumors on day 14 after the first treatment cycle shows that administration of either Apo2L/TRAIL or CPT-11 (10 or 20 mg/kg) alone significantly suppressed the growth of tumor 11124 ( fig. 2 a: p ! 0.05 in all cases), although this effect was not complete. More effective tumor inhibition was achieved with both combination therapies: both 20 mg/kg CPT-11 + Apo2L/TRAIL and 10 mg/kg CPT-11 + Apo2L/ TRAIL treatment inhibited tumor growth more effectively than each treatment alone (each p ! 0.01), and this significantly improved efficacy was still evident on day 42. In each group, 2 of the 5 tumors treated with combination therapy underwent regression and were completely eliminated. Although tumor 11501 was resistant to Apo2L/TRAIL alone, tumor 11501 was sensitive to CPT-11 and administration of CPT-11 alone at these doses resulted in a dosedependent inhibition of growth. After one treatment cycle, the tumors in the CPT-11 (both 20 and 10 mg/kg)-treated groups were significantly smaller than those of the control group (p ! 0.01). This inhibition of tumor growth was enhanced with combination therapy. Apo2L/ TRAIL combined with either 20 or 10 mg/kg CPT-11 inhibited tumor growth more effectively than either agent alone. At the end of the second cycle of treatment (day 43), 1 tumor in each group had completely regressed. Comparison of the palpable tumors in each group showed a statistically significant difference in tumor inhibition between the CPT-11 monotherapy at each dose and the corresponding combination therapy ( fig. 2 b, p ! 0.05 in each case). However, no treatment resulted in complete, longlasting elimination of all tumors.
While the improved effect of combination therapy over single therapy was found to be synergistic for tumor 11124 but not for tumor 11501, these data indicate that, in either the case of a tumor that is sensitive to Apo2L/ TRAIL alone or in one that is resistant, the combination of CPT-11 and Apo2L/TRAIL leads to enhanced tumor growth inhibition.
Histology of Tumors Treated with Apo2L/TRAIL
Histological analysis of tumor 11124 indicated that this is a moderately to poorly differentiated adenocarcinoma ( fig. 3 a) ; tumor 11501 is a moderately differentiated adenocarcinoma ( fig. 3 e) . To investigate the effect of treatment on these tumors further, representative tumors were removed from each group after 3 days of treatment. Even at this early time point, the Apo2L/TRAIL-sensitive tumor that had been treated with Apo2L/TRAIL consisted of comparatively more stromal cells and connective tissue than an untreated control tumor ( fig. 3 b) , while a tumor treated with CPT-11 alone (20 mg/kg), although slightly smaller, resembled the control ( fig. 3 c) . In comparison, a tumor treated with CPT-11 (20 mg/kg) in combination with Apo2L/TRAIL is significantly smaller and contains smaller, more scattered groups of viable tumor cells and proportionately more stromal cells ( fig. 3 d) . While the resistant tumors treated with either Apo2L/ TRAIL or CPT-11 alone have slightly fewer tumor cells ( fig. 3 f, g ), the tumor receiving combination therapy contains a noticeably higher proportion of connective tissue with smaller glands ( fig. 3 h) . Because sensitivity to Apo2L/TRAIL is reportedly p53 independent (see reviews [9, 18] ), we performed an immunohistochemical analysis of p53 expression in these two tumors. Results show moderate overexpression of p53 in the sensitive tumor 11124 ( fig. 3 i) and a high degree of overexpression in the resistant tumor 11501 ( fig. 3 j) . These results suggested that the Apo2L/TRAIL-resistant tumor might have a p53 mutation which resulted in accumulation of the abnormal protein. To further investigate this question, the human p53 DBD, where most of the p53 functional mutations have been described [19] , was amplified and sequenced. In both tumors, however, the p53 DBD sequence was wild type and no mutations were identified (data not shown).
To investigate the degree of apoptosis induced by treatment, TUNEL staining was performed on tumors following 3 days of treatment, and analysis was performed on a representative tumor from each group (for both tumors: 11124 and 11501) in the combination studies. On day 3, a tumor was removed from each experimental group, and the percentage of TUNEL-positive cells was enumerated over several microscopic fields (at least 2,000 cells were counted). Representative sections are shown in figure 4 . Tumor 11124 treated with Apo2L/TRAIL alone or in combination with CPT-11 (20 mg/kg) had more apoptotic cells than a control tumor or a tumor treated with CPT-11 alone: control 1.8%, Apo2L/TRAIL 10.9%, 20 mg/kg CPT-11 3.2% and the combination 18.3% apoptotic cells. Tumor 11501 treated with Apo2L/TRAIL and CPT-11 (20 mg/kg) also showed an increase in the number of apoptotic cells: control 2.3%, Apo2L/TRAIL 3.0%, 20 mg/kg CPT-11 5.0% and the combination therapy had 9.7% apoptotic cells.
Western Blot Analysis of the Expression of DR4 and DR5
To determine whether there is a difference between the expression of death receptors in the Apo2L/TRAILsensitive tumor (11124) and the Apo2L/TRAIL-resistant tumor (11501), tumor samples from mice in each treated group were removed on day 3 and total cellular expression of death receptors (DR4, DR5, DcR1 and DcR2) was assessed by Western blot analysis.
Both tumors were seen to express all four death receptors. However, slightly higher levels of both DR4 (1.9-fold) and DR5 (2.1-fold) were detected in the Apo2L/ TRAIL-sensitive tumor compared to the resistant tumor ( fig. 5 a) . This analysis also demonstrated that exposure to CPT-11 leads to modestly increased expression of DR5 in the Apo2L/TRAIL-sensitive tumor (1.5-fold), but not the Apo2L/TRAIL-resistant tumor ( fig. 5 b) . We also investigated the protein expression of BAX and Bcl-2, two members of the Bcl-2 family that have been reported to play a role in the sensitivity of colon carcinoma cells to Apo2L/ TRAIL [20] . The sensitive tumor was found to express a higher level of the pro-apoptotic protein BAX (3.5-fold) and a lower level of the anti-apoptotic molecule Bcl-2 (0.5-fold) compared to the Apo2L/TRAIL-resistant tumor ( fig. 5 c) . Furthermore, CPT-11 (20 mg/kg) treatment slightly increased BAX expression in both the Apo2L/ TRAIL-sensitive tumor (1.5-fold) and Apo2L/TRAIL-resistant tumor (1.7-fold; fig. 5 d) . Additionally, these tumors expressed equivalent levels of cFLIP, an important inhibitor of death receptor-mediated apoptosis, and CPT-11 treatment did not detectably affect this expression (data not shown).
Discussion
Previously, we have demonstrated that colon tumor xenografts derived from human tumors naturally exhibit sensitivity (to varying degrees) to Apo2L/TRAIL alone [7] . In this study, we have extended these observations and described the characterization of a human colon tumor that is inherently resistant to Apo2L/TRAIL, suggesting that, as previously observed in human pancreatic tumor xenografts [6] , human colon tumors can be expected to exhibit a full range of sensitivity to Apo2L/ TRAIL in a clinical setting. Various chemotherapeutic drugs have been shown to sensitize tumor cells to members of the TNF family and, furthermore, it has been shown that chemotherapeutic drugs can sensitize even Apo2L/TRAIL-resistant cancer cells to Apo2L/TRAIL [14, 21, 22] . Additionally, since there have been many reports demonstrating an enhanced efficacy of Apo2L/ TRAIL in combination with CPT-11 in colon cell lines both in vitro and in vivo [23] [24] [25] [26] and we have previously reported that combination therapy improved the response in a different Apo2L/TRAIL-sensitive human colon xenograft [7] , we aimed to compare the anti-tumor effects of Apo2L/TRAIL alone and in combination with CPT-11 on these two different human colon tumors, particularly to determine if this approach would be beneficial in the treatment of an Apo2L/TRAIL-resistant tumor. In this study, Apo2L/TRAIL treatment in combination with CPT-11 showed the greatest tumor growth inhibition not only against an Apo2L/TRAIL-sensitive tumor but, encouragingly, also against an Apo2L/TRAILresistant tumor. In fact, in the sensitive tumor, Apo2L/ TRAIL in combination with either dose of CPT-11 significantly inhibited tumor growth and this effect was synergistic. These results suggest that CPT-11 levels could be reduced if used in combination with Apo2L/TRAIL. This has the potential to reduce the toxic side effects of chemotherapeutics and may retard development of drug resistance. Following cessation of treatment, however, tumors treated with either Apo2L/TRAIL and/or CPT-11 re-grew and it remains to be investigated whether higher doses or different treatment schedules can prolong tumor growth inhibition.
Histological analysis in combination with the TUNEL assay confirms that the antitumor activity of Apo2L/ TRAIL can be attributed to the induction of apoptosis. Interestingly, although immunohistochemical visualization of p53 accumulation might suggest the presence of a p53 mutation in the Apo2L/TRAIL-resistant tumor (11501), sequencing of DBD, which is the region most often mutated [19] , did not identify a mutation. This disparity has been reported previously for colon tumors [27] and indicates that immunohistochemistry cannot reliably predict the p53 functional status. The presence of wild-type DBD correlates well with the observed sensitivity of both tumors to CPT-11, as previously reported to be required for chemosensitization to death ligand therapy [28] .
Our results predict that this inherent range of sensitivity to Apo2L/TRAIL is likely to be faced in a clinical situation. Previous reports have described multiple mechanisms that affect sensitivity to Apo2L/TRAIL-mediated apoptosis in various cell lines. These include expression levels of Apo2L/TRAIL receptors [22, 29] , the expression of inhibitory downstream molecules such as FLIPs [30] and IAPs [31] , and the activation of anti-apoptotic transcription factors such as NF B [32] . Additionally, some reports have demonstrated that Apo2L/TRAIL-induced apoptosis requires BAX for t-BID-mediated mitochondrial activation of caspase-9 [25, 33] , and loss of BAX results in resistance to death receptor-mediated apoptosis [20] . Another study suggests that Bcl-2 can inhibit Apo2L/ TRAIL-induced apoptosis [34] . We investigated the expression of Apo2L/TRAIL receptors and comparison of these two tumors shows that the Apo2L/TRAIL-resistant tumor has slightly lower expression of total cellular DR4 and DR5 by Western blot analysis than the sensitive tumor. However, a direct relationship to cell surface expression may not exist [35, 36] , and an analysis of total cellular expression and surface expression of Apo2L/TRAIL receptors needs to be carried out in a larger panel of tumors. We also investigated the protein expression of BAX and Bcl-2 and found that the Apo2L/TRAIL-sensitive tumor has a higher level of BAX and lower Bcl-2 expression than the Apo2L/TRAIL-resistant tumor. In order to reach any broad conclusions about the role of these factors in sensitivity and resistance, a larger panel of tumors needs to be investigated.
Some reports have shown that chemotherapeutic drugs can increase DR5 expression [37] and we examined this possibility in these tumors. Our results show a modest increase in DR5 expression in the Apo2L/TRAIL-sensitive human tumor following CPT-11 treatment, confirming our earlier observations in a different sensitive human colon tumor [7] . BAX expression was slightly increased in both tumors following CPT-11 treatment, in agreement with previous observations in a prostate tumor xenograft in vivo [26] . Again, further study in a larger number of tumors is needed to elucidate the mechanism(s) by which the CPT-11-Apo2L/TRAIL combination produces the enhanced anti-tumor effect as well as to more clearly define the differences in the response of a sensitive versus a resistant tumor.
In conclusion, the present study suggests that in a clinical setting, human colon tumors will inherently exhibit a wide range of sensitivity to Apo2L/TRAIL and some may even be comparatively resistant. However, our results demonstrate that Apo2L/TRAIL can augment the antitumor effect of CPT-11, even in Apo2L/TRAIL-resistant tumors. In fact, our results suggest that combined with Apo2L/TRAIL, doses of CPT-11 may be lowered, thus reducing toxicity and improving the quality of life of patients.
